Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GALMED PHARMACEUTICALS LTD.

(GLMD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Galmed Pharmaceuticals : Canaccord Genuity Adjusts Price Target on Galmed Pharmaceuticals to $20 From $25, Maintains Buy Rating

11/25/2020 | 01:14pm EST


ę MT Newswires 2020
All news about GALMED PHARMACEUTICALS LTD.
01/11Galmed Pharmaceuticals Gets Three New Patents to Treat Liver, Gut Diseases
MT
01/11GALMED PHARMACEUTICALS : Continues to Drive Innovation with Three New US Patents Granted f..
PU
01/11Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and..
PR
01/10GALMED PHARMACEUTICALS : announces positive results of Phase 1 study of Amilo-5MER - Form ..
PU
01/10Galmed announces positive results of Phase 1 study of Amilo-5MER
PR
01/10Galmed Pharmaceuticals Ltd. Announces Results of Phase 1 Clinical Trial of Amilo-5MER
CI
2021Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of AR..
PU
2021GALMED PHARMACEUTICALS : Q3 Earnings Snapshot
AQ
2021Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Mon..
CI
2021Galmed Pharmaceuticals Ltd. Announces New Positive Data from Ongoing ARMOR Study Open L..
CI
More news
Analyst Recommendations on GALMED PHARMACEUTICALS LTD.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -33,6 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,11x
Yield 2021 -
Capitalization 37,9 M 37,9 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 21
Free-Float 86,0%
Chart GALMED PHARMACEUTICALS LTD.
Duration : Period :
Galmed Pharmaceuticals Ltd. Technical Analysis Chart | GLMD | IL0011313900 | MarketScreener
Technical analysis trends GALMED PHARMACEUTICALS LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 1,47 $
Average target price 17,60 $
Spread / Average Target 1 101%
EPS Revisions
Managers and Directors
Allen Baharaff Chairman, President & Chief Executive Officer
Yohai Stenzler Controller
Liat Hayardeny Chief Scientific Officer
Guy Nehemya Chief Operating Officer
Shmuel Nir Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GALMED PHARMACEUTICALS LTD.-19.51%37
GILEAD SCIENCES, INC.-5.56%86 013
REGENERON PHARMACEUTICALS-1.60%64 979
VERTEX PHARMACEUTICALS4.59%58 397
WUXI APPTEC CO., LTD.-7.49%51 604
BIONTECH SE-41.44%36 465